Table 1. Summary of the Four Double-Blind, Placebo-Controlled Duloxetine Studies in Patients with MDD Included in the Pooled Analysis.

STUDY	TREATMENT DURATION	DRUG	PATIENTS	DRUG DOSE AND DESIGN
1	8 weeks	Placebo	90	–
(Nemeroff 2002)		Duloxetine	91	40 mg/day (20 mg b.i.d.)
		Duloxetine	84	80 mg/day (40 mg b.i.d.)
		Paroxetine	89	20 mg/day (q.d.)
2	8 weeks	Placebo	89	–
(Goldstein 2004)		Duloxetine	86	40 mg/day (20 mg b.i.d.)
		Duloxetine	91	80 mg/day (40 mg b.i.d.)
		Paroxetine	87	20 mg/day (q.d.)
3	8 weeks	Placebo	93	–
(Detke 2004)		Duloxetine	93	80 mg/day (40 mg b.i.d.)
		Duloxetine	93	120 mg/day (60 mg b.i.d.)
		Paroxetine	85	20 mg/day (q.d.)
4	8 weeks	Placebo	99	–
(Perahia 2006)		Duloxetine	93	80 mg/day (40 mg b.i.d.)
		Duloxetine	102	120 mg/day (60 mg b.i.d.)
		Paroxetine	97	20 mg/day (q.d.)

b.i.d., twice daily; MDD, major depressive disorder; q.d., once daily.